Lord Mendelsohn: To ask His Majesty's Government why a commissioning recommendation by NICE on Evusheld takes nearly a year to make; and whether they will expedite the appraisal of Evusheld by NICE by allocating it increased resources so the decision is made before 25 December.
Lord Mendelsohn: ...patients (a) who got COVID-19, (b) have been admitted to hospital with COVID-19, (c) who were admitted to intensive care with COVID-19, and (d) have died from COVID-19, since 17 March when Evusheld was approved for use in England.
Lord Mendelsohn: To ask His Majesty's Government, further to the report RAPID C-19 Oversight Group report: review of Evusheld by the RAPID C-19 Oversight Group, published on 6 October, whether they will (1) consult a wider group with more diverse viewpoints and expertise to make a recommendation on the efficacy of Evusheld, and (2) engage other committees with expertise like SAGE and the JCVI on this treatment.
Daisy Cooper: To ask the Secretary of State for Health and Social Care, whether her Department has had discussions with the Centre for Disease Control in the US on their use of Evusheld as a pre-exposure prophylaxis to prevent Covid-19 in people who are moderately to severely immunocompromised.
Lord Mendelsohn: To ask His Majesty's Government whether they have entered negotiations with AstraZeneca in relation to the cost of procuring Evusheld.
Lord Mendelsohn: ...with representatives of the 125 expert clinicians from all four nations of the UK covering 17 relevant medical disciplines and advising the APPG Vulnerable Groups to Pandemics on the efficacy of Evusheld.
Lord Mendelsohn: To ask His Majesty's Government when they expect the NICE assessment of Evusheld to be completed; and whether, if approved, the treatment will be provided for patients in England this winter.
Lord Mendelsohn: ...Majesty's Government what consultation process took place which led to the decision by the Secretary of State for Health and Social Care and the Chief Medical Officer not to pursue procurement of Evusheld; whether they will publish minutes of the meeting where this decision was made; and who attended that meeting.
Zarah Sultana: To ask the Secretary of State for Health and Social Care, when she expects the National Institute for Health and Care Excellence to conclude its appraisal of Evusheld.
Andrew Gwynne: To ask the Secretary of State for Health and Social Care, whether his Department plans to meet with patient groups, charities and clinicians representing the #Forgotten500k campaign.
Edward Leigh: ...of State for Health and Social Care, what support her Department is providing to immunosuppressed people to help prevent the spread of covid-19; what progress the government has made on approving Evusheld for use by those people; and if she will make a statement.
Matt Vickers: To ask the Secretary of State for Health and Social Care, whether the Government has made an assessment of the impact of delaying the procurement of covid-19 treatment Evusheld on people who are immunocompromised; and if he will review the decision not to procure Evusheld for use in treatment of vulnerable people during winter 2022-23.
Alan Campbell: To ask the Secretary of State for Health and Social Care, whether her Department plans to review its current policy on the use of Evusheld in the NHS in winter 2022-23.
Daisy Cooper: To ask the Secretary of State for Health and Social Care, whether his Department has (a) sought and (b) received advice from immunologists on the effectiveness of Evusheld.
Alexander Stafford: To ask the Secretary of State for Health and Social Care, if she will review her department’s decision not to permit the use of Evusheld for patient groups vulnerable to covid-19 this winter.
Lord Mendelsohn: To ask His Majesty's Government what reasons the RAPID C-19 initiative gave for advising them against providing Evusheld to the immunocompromised in the UK.
Lord Mendelsohn: ...to the letter from the then Secretary of State for Health and Social Care on 6 September to Gemma Peters, Chief Executive of Blood Cancer UK, which states that “proceeding to patient access [to Evusheld is] considered to outweigh the risks of not providing this treatment in the current pandemic context”, what are the risks of not providing Evusheld.
Lord Mendelsohn: ...Regulatory Agency claimed in their 6 September letter to Gemma Peters, Chief Executive of Blood Cancer UK, that there is ongoing uncertainty about whether the results from the PROVENT study on Evusheld shed light on clinical effectiveness, given this study supported their decision to approve single and double doses of Evusheld in the UK in March.
Daisy Cooper: To ask the Secretary of State for Health and Social Care, with reference to the Minister of Health's oral contribution on 13 October 2022, Official Report, column 107WH, by what date he expects to complete the review of the (a) Francis Crick Institute study and (b) Lancet Journal article; and if he set out details of how that review will be conducted.
Daisy Cooper: ...for Health and Social Care, pursuant to the contribution by the Minister of State at the Department of Health and Social Care on 12 October to the Westminster Hall debate on the Procurement of Evusheld, Official Report, column 107WH, on what date she plans to announce the accelerated timetable for the NICE assessment of Evusheld.